Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
- Trade
- Markets
- Copy
- Contests
- News
- 24/7
- Calendar
- Q&A
- Chats
Trending
SYMBOL
LAST
BID
ASK
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6864.06
6864.06
6864.06
6895.79
6858.32
+6.94
+ 0.10%
--
DJI
Dow Jones Industrial Average
47910.70
47910.70
47910.70
48133.54
47871.51
+59.77
+ 0.12%
--
IXIC
NASDAQ Composite Index
23536.96
23536.96
23536.96
23680.03
23506.00
+31.83
+ 0.14%
--
USDX
US Dollar Index
98.980
99.060
98.980
99.060
98.740
0.000
0.00%
--
EURUSD
Euro / US Dollar
1.16363
1.16371
1.16363
1.16715
1.16277
-0.00082
-0.07%
--
GBPUSD
Pound Sterling / US Dollar
1.33223
1.33233
1.33223
1.33622
1.33159
-0.00048
-0.04%
--
XAUUSD
Gold / US Dollar
4210.73
4211.07
4210.73
4259.16
4194.54
+3.56
+ 0.08%
--
WTI
Light Sweet Crude Oil
60.025
60.057
60.025
60.236
59.187
+0.642
+ 1.08%
--
- All
- Chatrooms
- Groups
- Friends
Connecting
.
.
.
- All
- Russia-Ukraine Conflict
- Middle East Flashpoint
BeOne Medicines Lymphoma Drug Gets FDA Priority Review
Dow Jones Newswires
By Adriano Marchese
BeOne Medicines said U.S. regulators have agreed to fast-track the review its new drug to treat adults with mantle cell lymphoma, a form of blood cancer.
The cancer treatment company said Wednesday that the Food and Drug Administration has accepted and granted priority review to a new drug application for sonrotoclax, a new BCL2 inhibitor intended to treat adult patients with relapsed or refractory mantle cell lymphoma.
Mantle cell lymphoma is a rare, fast-growing blood cancer that starts in the lymph nodes.
The decision was based on data from a phase 1/2 study which enrolled 125 adult patients with the specific type of blood cancer who had received prior treatment. The trial results found that sonorotoclax achieved its primary endpoints of overall response rate, and also showed promising results across several secondary efficacy endpoints, it said.
"Sonrotoclax is advancing with remarkable speed, from breakthrough therapy designation to priority review, all within a short window," Global Head of Research and Development at BeOne, Lai Wang, said.
Write to Adriano Marchese at adriano.marchese@wsj.com
Risk Warnings and Disclaimers
You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
Copyright © 2025 FastBull Ltd
728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG
Risk Disclosure
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Become a signal provider
Help Center
Dark Mode
Price Up/Down Colors
Log In
Sign Up